文献速递慢性肾脏病肾小球疾病

维立奴拉德联合非布司他强化降尿酸对2型糖尿病合并高尿酸血症患者白蛋白尿的影响:一项随机试验

Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
PubMed 文献 · Am J Kidney Dis · 2020-10-29

这项2期随机双盲安慰剂对照试验纳入60例2型糖尿病合并高尿酸血症和蛋白尿患者,比较维立奴拉德9mg联合非布司他80mg与安慰剂治疗24周的效果。主要终点为12周尿白蛋白肌酐比值(UACR)较基线的变化,联合治疗组UACR降低39.4%,血尿酸显著下降,耐受性良好,但样本量小、随访短,对肾功能保护作用待更大规模研究验证。

要点

  • 维立奴拉德联合非布司他12周使UACR降低39.4%(90%CI -61.8%至-3.8%)。
  • 联合治疗24周UACR降低49.3%,血尿酸降低63.7%。
  • eGFR、血肌酐及胱抑素C未见临床有意义变化。

核心结论

  • 在2型糖尿病合并高尿酸血症和蛋白尿患者中,维立奴拉德联合非布司他可降低白蛋白尿和血尿酸水平。

研究设计与样本

  • 2期、多中心、前瞻性、随机、双盲、平行组、安慰剂对照试验,共纳入60例患者(联合治疗组32例,安慰剂组28例)。

主要发现

  • 治疗1、12、24周后,联合治疗组UACR较安慰剂组分别降低38.6%(90%CI -60.9%至-3.6%)、39.4%(90%CI -61.8%至-3.8%)和49.3%(90%CI -68.2%至-19.0%)。
  • 治疗12周和24周后,联合治疗组血尿酸较安慰剂组分别降低59.6%和63.7%。
  • 未观察到eGFR、血肌酐或血清胱抑素C的临床有意义变化,联合治疗耐受性良好。

局限性

  • 样本量和研究时长不足以确定维立奴拉德联合非布司他对UACR和肾小球滤过率的明确影响。
  • 排除CKD 4期和5期患者限制了结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Hyperuricemia has been implicated in the development and progression of chronic kidney disease. Verinurad is a novel, potent, specific urate reabsorption inhibitor. We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM). STUDY DESIGN: Phase 2, multicenter, prospective, randomized, double-blind, parallel-group, placebo-controlled trial. SETTING & PARTICIPANTS: Patients 18 years or older with hyperuricemia, albuminuria, and T2DM. INTERVENTION: Patients randomly assigned 1:1 to verinurad (9mg) plus febuxostat (80mg) or matched placebo once daily for 24 weeks. OUTCOMES: The primary end point was change in urinary albumin-creatinine ratio (UACR) from baseline after 12 weeks' treatment. Secondary end points included safety and tolerability and effect on glomerular filtration. RESULTS: 60 patients were enrolled (n=32, verinurad and febuxostat; n=28, placebo). UACRs after treatment with verinurad plus febuxostat were lower than after placebo at 1, 12, and 24 weeks: -38.6% (90% CI, -60.9% to-3.6%), -39.4% (90% CI, -61.8% to-3.8%), and-49.3% (90% CI, -68.2% to-19.0%), respectively. Serum urate levels after treatment with verinurad plus febuxostat were 59.6% and 63.7% lower than after placebo at 12 and 24 weeks, respectively. No clinically meaningful changes were observed in estimated glomerular filtration rate or serum creatinine or serum cystatin C concentrations. Verinurad plus febuxostat was well tolerated. LIMITATIONS: Sample size and study duration were insufficient to evaluate definitive effects of verinurad plus febuxostat on UACR and glomerular filtration. Generalizability was limited by exclusion of patients with stages 4 and 5 chronic kidney disease. CONCLUSIONS: Verinurad plus febuxostat reduced albuminuria and lowered serum urate concentrations in patients with T2DM, albuminuria, and hyperuricemia. Definitive assessment of their combined impact on preservation of kidney function awaits larger clinical studies. FUNDING: This study was supported by AstraZeneca. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03118739.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Stack AG, Dronamraju N, Parkinson J, et al. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. Am J Kidney Dis. 2020. PMID: 33130235. doi:10.1053/j.ajkd.2020.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。